Cover Image
Market Research Report

Global Respiratory Complications Therapeutics Market to 2022 - Innovative Pneumonia and Pulmonary Arterial Hypertension Therapies Dominate Varied Disease Market

Published by GlobalData Product code 485006
Published Content info 197 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Respiratory Complications Therapeutics Market to 2022 - Innovative Pneumonia and Pulmonary Arterial Hypertension Therapies Dominate Varied Disease Market
Published: March 1, 2017 Content info: 197 Pages
Description

Executive Summary

Respiratory complications are a diverse set of indications that include respiratory disorders, cardiovascular disorders and infectious diseases. They are therefore associated with a broad range of underlying pathophysiology, which is reflected in the range of therapies in development in the pipeline. Overall, there are 843 products in active development in the respiratory complications pipeline. However, this constitutes numerous individual indications, each of which is typically relatively small in terms of the number of pipeline products in development.

The most prominent individual indications in terms of respiratory complications therapeutics development are Pneumonia, Tuberculosis (TB), Respiratory Syncytial Virus (RSV) and Pulmonary Arterial Hypertension (PAH), which reflects the active nature of these indications in terms of overall product development.

In spite of a small late-stage pipeline, the respiratory complications market is forecast to grow moderately over the forecast period, from a value of $21.8 Billion in 2015 to $30.2 Billion in 2022, at a compound annual growth rate (CAGR) of 4.7%. This growth will be predominantly driven by already marketed products, rather than the approval of pipeline products, which are expected to have a limited impact on the market. Furthermore, generic impact on the market will be limited in terms of value, given the very low cost of generics typically used.

There are few drugs that generate substantial revenue in the current respiratory complications market, with only one generating over $1 Billion from revenues specific to these complications. This is the Prevnar family pneumococcal disease vaccine, which has been approved for a broad spectrum of patients, ranging from six-week-old infants to adults of 50 and over. In 2015 the vaccine family generated $6.3 Billion, and this level of revenue is expected to remain relatively stable over the forecast period.

Pfizer is expected to maintain its position as market leader throughout the entire forecast period. Although the company has a large number of drugs active in this area, spread across pneumonia and pulmonary embolism, it is predominantly the pneumonia vaccine Prevnar that drives its revenue derived from respiratory complications. Pfizer is expected to generate $7.3 Billion by 2022, rising from $6.9 Billion in 2015 at a CAGR of 0.8%. This marginal growth is attributed to the limited revenue growth of Prevnar, as well as some revenue growth for the anticoagulant Eliquis (apixaban), which is expected to generate $642.8m from respiratory complications by 2022.

The report "Global Respiratory Complications Therapeutics Market to 2022 - Innovative Pneumonia and Pulmonary Arterial Hypertension Therapies Dominate Varied Disease Market" provides an introduction to the respiratory complications therapeutics market, including disease epidemiology, symptoms, etiology, pathophysiology, co-morbidities and complications, diagnosis and prognosis.

In depth, it provides the following -

  • Provides an overview of the landscape for marketed products for respiratory complications, including product profiles of key marketed products and revenue projections for each of these drugs.
  • Analyzes the respiratory complication therapeutics pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and mechanism of action, plus an analysis of the key indications in the pipeline: pneumonia, TB, RSV and PAH.
  • Provides forecast projections to 2022 on a global level, with forecasts also provided for the US, plus aggregate revenue forecasts of the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan.
  • Provides the company landscape in the respiratory complications therapeutics market, with an analysis of the key players, the types of company involved in this disease cluster, whether this disease cluster comprises a large proportion of each company's pipeline portfolio, and total revenue.
  • Analyzes trends in co-development and licensing deals relating to respiratory complications therapeutics.

Scope

The respiratory complications market already contains commercially successful products.

  • Which classes of drug dominate the market?
  • What additional benefits have newly approved therapies brought to the market?

The respiratory complications pipeline is large, with significant diversity in terms of molecule types and targets.

  • Which molecular targets appear most frequently in the pipeline?
  • What are the commercial prospects for the most promising late-stage pipeline products?

The respiratory complications market is forecast to grow from $21.8 billion in 2015 to $30.2 billion in 2022, at a compound annual growth rate of 4.7%.

  • Which products are forecast to drive this substantial growth?
  • Will generic competition have a significant impact on the market over the forecast period?

The company landscape is becoming increasingly competitive.

  • What are the leading companies in terms of market share?
  • Which companies are forecast to experience the greatest growth in market share?
  • What are the drivers of growth for key companies in the market?
  • How dependent are the key companies on this disease cluster for revenue?

Reasons to buy

This report will allow you to -

  • Understand the current clinical and commercial landscape through a comprehensive study of disease epidemiology, pathogenesis, symptoms, diagnosis and prognosis for the key indications covered in the report, which include pneumonia, TB, RSV and PAH.
  • Assess the current treatment landscape, with product profiles covering prominent marketed therapies, including revenue forecasts.
  • Analyze the respiratory complications pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.
  • Predict growth in market size, with in-depth market forecasting from 2015 to 2022. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
  • Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies in the market are on revenue derived from respiratory complications products. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market.
  • Identify commercial opportunities in the respiratory complications deals landscape by analyzing trends in licensing and co-development deals.
Table of Contents
Product Code: GBIHC433MR

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Therapy Area Introduction
  • 2.2. Symptoms
    • 2.2.1. Pneumonia
    • 2.2.2. RSV
    • 2.2.3. PAH
    • 2.2.4. Tuberculosis
  • 2.3. Diagnosis
    • 2.3.1. Pneumonia
    • 2.3.2. RSV
    • 2.3.3. PAH
    • 2.3.4. Tuberculosis
  • 2.4. Etiology and Pathophysiology
    • 2.4.1. Pneumonia
    • 2.4.2. RSV
    • 2.4.3. PAH
    • 2.4.4. Tuberculosis
  • 2.5. Epidemiology
    • 2.5.1. Pneumonia
    • 2.5.2. RSV
    • 2.5.3. PAH
    • 2.5.4. Tuberculosis
  • 2.6. Comorbidities and Complications
    • 2.6.1. Pneumonia
    • 2.6.2. RSV
    • 2.6.3. PAH
    • 2.6.4. Tuberculosis
  • 2.7. Prognosis
    • 2.7.1. Pneumonia
    • 2.7.2. RSV
    • 2.7.3. PAH
    • 2.7.4. Tuberculosis
  • 2.8. Treatment
    • 2.8.1. Antibiotics
    • 2.8.2. Antiviral Drugs
    • 2.8.3. Vaccines
    • 2.8.4. Antihypertensive drugs
    • 2.8.5. Anticoagulants
    • 2.8.6. Non-Pharmacological Treatments

3. Marketed Products

  • 3.1. Overview
  • 3.2. Prevnar 13. - Pfizer
  • 3.3. Synflorix - GlaxoSmithKline
  • 3.4. Uptravi - Actelion
  • 3.5. Opsumit - Actelion
  • 3.6. Eliquis - Bristol-Myers Squibb and Pfizer
  • 3.7. Xarelto - Bayer
  • 3.8. Synagis - Medimmune
  • 3.9. Ventolin - GlaxoSmithKline
  • 3.10. Infanrix and Boostrix - GlaxoSmithKline

4. Pipeline Landscape Assessment

  • 4.1. Overview
  • 4.2. Pipeline Development Landscape
  • 4.3. Molecular Targets in the Pipeline
  • 4.4. Clinical Trials
    • 4.4.1. Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.2. Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.3. Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.4. Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.5. Conclusion
  • 4.5. Assessment of Key Pipeline Products
    • 4.5.1. Solithera - Cempra
    • 4.5.2. Carbavance (meropenem and vaborbactam) -The Medicines Company
    • 4.5.3. Respiratory Syncytial Virus Vaccine - Novavax
    • 4.5.4. Conclusion

5. Multi-scenario Market Forecast to 2022

  • 5.1. Overall Market Size
  • 5.2. Generic Penetration
  • 5.3. Revenue Forecast by Molecular Target and Drug Category
    • 5.3.1. Vaccines
    • 5.3.2. G-Protein Coupled Receptors
    • 5.3.3. Enzyme Targets
    • 5.3.4. Bacterial and Viral Targets
  • 5.4. Revenue and Market Share Analysis by Company
    • 5.4.1. Pfizer - Prevnar Dominates Respiratory Complications Revenue
    • 5.4.2. Actelion - Rapid Growth of PAH Therapies to Create a Strong Market Position
    • 5.4.3. GSK - Vast Product Portfolio Will Help Maintain a Strong Market Position
    • 5.4.4. Bayer - Despite Limited Portfolio, Xarelto Performance Sufficient to Establish Strong Market Position
    • 5.4.5. Bristol-Myers Squibb - Growing Eliquis Revenue to Improve Respiratory Complications Market Position
    • 5.4.6. Novavax - Approval of RSV Vaccine Will Help Establish Market Presence
    • 5.4.7. United Therapeutics - Variant Treprostinil Formulation to Form Cornerstone of Market Presence

6. Company Analysis and Positioning

  • 6.1. Company Landscape
  • 6.2. Marketed and Pipeline Portfolio Analysis

7. Strategic Consolidations

  • 7.1. Licensing Deals
    • 7.1.1. Deals by Region, Value and Year
    • 7.1.2. Deals by Stage of Development and Value
    • 7.1.3. Deals by Molecule Type, Mechanism of Action and Value
    • 7.1.4. Licensing Deals Valued Above $100m
  • 7.2. Co-development Deals
    • 7.2.1. Deals by Region, Value and Year
    • 7.2.2. Deals by Stage of Development and Value
    • 7.2.3. Deals by Molecule Type and Value
    • 7.2.4. Co-development Deals Valued Above $100m

8. Appendix

  • 8.1. Bibliography
  • 8.2. All Pipeline Drugs by Phase of Development
    • 8.2.1. Discovery
    • 8.2.2. Preclinical
    • 8.2.3. IND/CTA-filed
    • 8.2.4. Phase I
    • 8.2.5. Phase II
    • 8.2.6. Phase III
    • 8.2.7. Pre-registration
    • 8.2.8. Unknown
  • 8.3. Abbreviations
  • 8.4. Methodology
    • 8.4.1. Coverage
    • 8.4.2. Secondary Research
    • 8.4.3. Market Size and Revenue Forecasts
    • 8.4.4. Pipeline Analysis
    • 8.4.5. Competitive Landscape
  • 8.5. Contact Us
  • 8.6. Disclaimer

List of Tables

  • Table 1: Respiratory Complications Therapeutics Market, Global, Key Marketed Products and Approved Indications, 2017
  • Table 2: Respiratory Complications Therapeutics Market, Global, Prevnar 13 Indications, 2017
  • Table 3: Respiratory Complications Therapeutics Market, Global, Synflorix Indications, 2017
  • Table 4: Respiratory Complications Therapeutics Market, Global, Uptravi Indications, 2017
  • Table 5: Respiratory Complications Therapeutics Market, Global, Opsumit Indications, 2017
  • Table 6: Respiratory Complications Therapeutics Market, Global, Eliquis Indications, 2017
  • Table 7: Respiratory Complications Therapeutics Market, Global, Xarelto Indications, 2017
  • Table 8: Respiratory Complications Therapeutics Market, Global, Synagis Indications, 2017
  • Table 9: Respiratory Complications Therapeutics Market, Global, Ventolin Indications, 2017
  • Table 10: Respiratory Complications Therapeutics Market, Global, Infanrix Indications, 2017
  • Table 11: Respiratory Complications Therapeutics Market, Global, Annual Revenue Forecast for Key Products ($m), 2015-2022
  • Table 12: Respiratory Complications Therapeutics Market, Global, Forecast Revenue by Company, 2015-2022
  • Table 13: Respiratory Complications Therapeutics Market, Global, Licensing Deals Valued above $100m, 2006-2017
  • Table 14: Respiratory Complications Therapeutics Market, Global, Co-development Deals above $100m, 2006-2017
  • Table 15: Respiratory Complications Therapeutics Market, Global, Pipeline Products, Discovery, 2017
  • Table 16: Respiratory Complications Therapeutics Market, Global, Pipeline Products, Preclinical, 2017
  • Table 17: Respiratory Complications Therapeutics Market, Global, Pipeline Products, IND/CTA-Filed, 2017
  • Table 18: Respiratory Complications Therapeutics Market, Global, Pipeline Products, Phase I, 2017
  • Table 19: Respiratory Complications Therapeutics Market, Global, Pipeline Products, Phase II, 2017
  • Table 20: Respiratory Complications Therapeutics Market, Global, Pipeline Products, Phase III, 2017
  • Table 21: Respiratory Complications Therapeutics Market, Global, Pipeline Products, Pre-Registration, 2017
  • Table 22: Respiratory Complications Therapeutics Market, Global, Pipeline Products, Unknown, 2017

List of Figures

  • Figure 1: Respiratory Complications Therapeutics Market, Global, Epidemiology Patterns for Pneumonia Incidence, 2015-2022
  • Figure 2: Respiratory Complications Therapeutics Market, Global, Epidemiology Patterns for Pneumococcal Vaccinations (million), 2015-2022
  • Figure 3: Respiratory Complications Therapeutics Market, Global, Epidemiology Patterns for PAH, 2015-2022
  • Figure 4: Respiratory Complications Therapeutics Market, Global, Epidemiology Patterns for Tuberculosis, 2015-2022
  • Figure 5: Respiratory Complications Therapeutics Market, Global, Prevnar 13 Revenue Forecast, 2015-2022
  • Figure 6: Respiratory Complications Therapeutics Market, Global, Synflorix Revenue Forecast, 2015-2022
  • Figure 7: Respiratory Complications Therapeutics Market, Global, Uptravi Revenue Forecast, 2016-2022
  • Figure 8: Respiratory Complications Therapeutics Market, Global, Opsumit Revenue Forecast, 2015-2022
  • Figure 9: Respiratory Complications Therapeutics Market, Global, Eliquis Revenue Forecast, 2015-2022
  • Figure 10: Respiratory Complications Therapeutics Market, Global, Xarelto Revenue Forecast, 2015-2022
  • Figure 11: Respiratory Complications Therapeutics Market, Global, Synagis Revenue Forecast, 2015-2022
  • Figure 12: Respiratory Complications Therapeutics Market, Global, Ventolin Revenue Forecast, 2015-2022
  • Figure 13: Respiratory Complications Therapeutics Market, Global, Infanrix Revenue Forecast, 2015-2022
  • Figure 14: Respiratory Complications Therapeutics Market, Global, Boostrix Revenue Forecast, 2015-2022
  • Figure 15: Respiratory Complications Therapeutics Market, Global, Pipeline by Stage of Development, Molecule Type and Program Type, 2017
  • Figure 16: Respiratory Complications Therapeutics Market, Global, Pipeline for Key Indications by Stage of Development, 2017
  • Figure 17: Respiratory Complications Therapeutics Market, Global, Pipeline for Key Indications by Molecule Type, 2017
  • Figure 18: Respiratory Complications Therapeutics Market, Global, Pipeline by Molecular Target, 2017
  • Figure 19: Respiratory Complications Therapeutics Market, Global, Pipeline for Key Indications by Molecular Target, 2017
  • Figure 20: Respiratory Complications Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2017
  • Figure 21: Respiratory Complications Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2017
  • Figure 22: Respiratory Complications Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2017
  • Figure 23: Respiratory Complications Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2017
  • Figure 24: Respiratory Complications Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2017
  • Figure 25: Respiratory Complications Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2017
  • Figure 26: Respiratory Complications Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2017
  • Figure 27: Respiratory Complications Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2017
  • Figure 28: Respiratory Complications Therapeutics Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2017
  • Figure 29: Respiratory Complications Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2017
  • Figure 30: Respiratory Complications Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2017
  • Figure 31: Respiratory Complications Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2017
  • Figure 32: Respiratory Complications Therapeutics Market, Global, Clinical Program Size by Stage of Development (participants), 2006-2017
  • Figure 33: Respiratory Complications Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2017
  • Figure 34: Respiratory Complications Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2017
  • Figure 35: Respiratory Complications Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2017
  • Figure 36: Respiratory Complications Therapeutics Market, Global, Revenue Forecast for Solithera ($m), 2017-2022
  • Figure 37: Respiratory Complications Therapeutics Market, Global, Revenue Forecast for Carbavance ($m), 2017-2022
  • Figure 38: Respiratory Complications Therapeutics Market, Global, Revenue for Respiratory Syncytial Virus Vaccine ($m), 2018-2022
  • Figure 39: Respiratory Complications Therapeutics Market, Global, Market Size ($bn), 2015-2022
  • Figure 40: Respiratory Complications Therapeutics Market, Global, Annual Revenue by Generic Products ($m), 2015-2022
  • Figure 41: Respiratory Complications Therapeutics Market, Global, Annual Revenue Forecast for Vaccines ($bn), 2015-2022
  • Figure 42: Respiratory Complications Therapeutics Market, Global, Annual Revenue Forecast for Drugs Targeting G-Protein Coupled Receptors ($bn), 2015-2022
  • Figure 43: Respiratory Complications Therapeutics Market, Global, Annual Revenue Forecast for Drugs Targeting Enzymes ($bn), 2015-2022
  • Figure 44: Respiratory Complications Therapeutics Market, Global, Annual Revenue Forecast for Drugs with Bacterial/Viral Targets ($bn), 2015-2022
  • Figure 45: Respiratory Complications Therapeutics Market, Global, Company Analysis Matrix, 2015-2022
  • Figure 46: Respiratory Complications Therapeutics Market, Global, Forecast Market Share by Company (%), 2015-2022
  • Figure 47: Respiratory Complications Therapeutics Market, Global, Companies by Compound Annual Growth Rate (%), Base Year-2022
  • Figure 48: Respiratory Complications Therapeutics Market, Global, Pfizer Annual Revenue Forecast ($bn), 2015-2022
  • Figure 49: Respiratory Complications Therapeutics Market, Global, Actelion Annual Revenue ($bn), 2015-2022
  • Figure 50: Respiratory Complications Therapeutics Market, Global, GSK Annual Revenue ($bn), 2015-2022
  • Figure 51: Respiratory Complications Therapeutics Market, Global, Bayer Annual Revenue ($bn), 2015-2022
  • Figure 52: Respiratory Complications Therapeutics Market, Global, Bristol-Myers Squibb Annual Revenue ($bn), 2015-2022
  • Figure 53: Respiratory Complications Therapeutics Market, Global, Novavax Annual Revenue ($m), 2018-2022
  • Figure 54: Respiratory Complications Therapeutics Market, Global, United Therapeutics Annual Revenue ($bn), 2015-2022
  • Figure 55: Respiratory Complications Therapeutics Market, Global, Cluster by Growth and Market Share, 2015-2022
  • Figure 56: Respiratory Complications Therapeutics Market, Global, Companies by Type, 2017
  • Figure 57: Respiratory Complications Therapeutics Market, Global, High-Activity and Late-Stage Developers by Level of Specialization, 2017
  • Figure 58: Respiratory Complications Therapeutics Market, Global, Proportion of Total Company Revenue Attributed to Respiratory Complications, 2015-2022
Back to Top